Title |
The HYPERFlax trial for determining the anti-HYPERtensive effects of dietary flaxseed in newly diagnosed stage 1 hypertensive patients: study protocol for a randomized, double-blinded, controlled clinical trial
|
---|---|
Published in |
Trials, June 2014
|
DOI | 10.1186/1745-6215-15-232 |
Pubmed ID | |
Authors |
Stephanie PB Caligiuri, Brian Penner, Grant N Pierce |
Abstract |
In 2013 the World Health Organization deemed hypertension as a global crisis as it is the leading risk factor attributed to global mortality. Therefore, there is a great need for effective alternative treatment strategies to combat a condition that affects 40% of adults worldwide. Recently, the FlaxPAD Trial observed a significant reduction in systolic and diastolic blood pressure in hypertensive patients with peripheral arterial disease that consumed 30 g of milled flaxseed per day for one year. However, these patients were already on anti-hypertensive medication. Therefore, there is a need to assess if dietary flaxseed can effectively reduce blood pressure in the absence of peripheral arterial disease and anti-hypertensive medication in newly diagnosed hypertensive patients. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 2 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 2 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 1 | <1% |
Canada | 1 | <1% |
Unknown | 129 | 98% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 19 | 15% |
Student > Bachelor | 17 | 13% |
Researcher | 12 | 9% |
Student > Ph. D. Student | 11 | 8% |
Student > Doctoral Student | 8 | 6% |
Other | 25 | 19% |
Unknown | 39 | 30% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 27 | 21% |
Nursing and Health Professions | 23 | 18% |
Agricultural and Biological Sciences | 7 | 5% |
Biochemistry, Genetics and Molecular Biology | 6 | 5% |
Engineering | 3 | 2% |
Other | 16 | 12% |
Unknown | 49 | 37% |